Annovis Bio, Inc.ANVSNYSE
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank71
3Y CAGR-8.2%
5Y CAGR-16.5%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-8.2%/yr
Quarterly compound
5Y CAGR
-16.5%/yr
Recent acceleration
Percentile
P71
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
3 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 39.10% |
| Q3 2025 | 21.88% |
| Q2 2025 | 3.00% |
| Q1 2025 | 0.26% |
| Q4 2024 | 85.85% |
| Q3 2024 | -53.51% |
| Q2 2024 | -11.20% |
| Q1 2024 | -26.84% |
| Q4 2023 | -35.65% |
| Q3 2023 | 67.48% |
| Q2 2023 | 6.11% |
| Q1 2023 | 25.41% |
| Q4 2022 | 50.56% |
| Q3 2022 | 2.22% |
| Q2 2022 | 87.66% |
| Q1 2022 | -25.47% |
| Q4 2021 | 108.87% |
| Q3 2021 | -24.32% |
| Q2 2021 | -23.65% |
| Q1 2021 | 69.21% |
| Q4 2020 | 96.44% |
| Q3 2020 | -16.06% |
| Q2 2020 | 1188.98% |
| Q1 2020 | -91.28% |
| Q4 2019 | 37762.99% |
| Q3 2019 | -66.67% |
| Q2 2019 | 0.32% |
| Q1 2019 | -54.69% |
| Q4 2018 | 0.14% |
| Q3 2018 | -51.27% |
| Q2 2018 | -52.89% |
| Q1 2018 | 0.00% |